ESR1 and breast carcinoma: Based on the expression and function of estrogen receptors in breast cancer, anti-estrogen receptor endocrine therapy was applied for millions of breast cancer patients in clinics, while about 33% of estrogen-receptor-positive malignancies have an intrinsic potential to develop hormone resistance [48].